RxDoctor Payments DataLook up a doctor →

George Solomon

Critical Care Medicine · Birmingham, ALNPI 1316140403

Payments from drug & device makers

$1,379,574in general payments, 2019–2025

Across 707 payments — averaging $1951.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$809K
  • Vertex$440K
  • AstraZeneca$67K
  • Sanofi US Services Inc.$41K
  • GSK$11K
  • Electromed, Inc.$5K
  • plus $7K from 14 others

What the payments were for

  • Consulting fees$59,91753%
  • Speaking & faculty fees$27,22524%
  • Travel & lodging$18,89917%
  • Food & beverage$6,6246%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,379,574 in reported general payments places this provider in the 95th percentile of 73 critical care medicine providers in Alabama.

See all critical care medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$25,633
Medicare patients
296
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft81$2,046,113
ZenpepLipase/Protease/Amylase15$121,495
Prolastin CAlpha-1-Proteinase Inhibitor13$112,851
Dupixent PenDupilumab12$40,960
EliquisApixaban17$9,546
Breo ElliptaFluticasone/Vilanterol19$9,419
MultaqDronedarone Hcl12$9,088
Azithromycin144$5,161
Meropenem19$4,678
Wixela InhubFluticasone Propion/Salmeterol14$2,797
Albuterol Sulfate HfaAlbuterol Sulfate90$2,672
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,511
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,958
Fluticasone Propionate25$534
Diphenhydramine Hcl18$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta$439,647$2,046,11381 claims
GSKBreo Ellipta$11,368$9,41919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 critical care medicine providers in Alabama.

Other critical care medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →